Dyadic International INC 10-Q quarterly reports

Dyadic International reported a net loss of $2.12 million for Q2 2026, with significant concerns remaining about its ability to continue as a going concern.

Dyadic International's Q1 2026 report shows a significant 182.3% revenue increase driven by research and development, grant, and license/milestone revenues, alongside a narrowed net loss.

Dyadic International, Inc. reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, despite securing new grants and completing a public offering to fund its strategic shift towards commercializing non-therapeutic protein platforms.

Dyadic International, Inc. (DYAI) reported a reduced net loss and increased total revenue for Q2 2025, while addressing Nasdaq compliance and securing $5.3 million in post-period capital.

Dyadic International, Inc. released its first quarter 2025 financial results, marked by decreased revenue and a net loss, but with sufficient cash reserves for the next twelve months.

Dyadic International's strategic focus on licensing and collaboration agreements fuels revenue growth in the third quarter of 2024, despite ongoing investments in research and development.

Dyadic International's Q2 2024 results reflect a strategic shift towards commercialization, with decreased revenue due to winding down research collaborations, offset by progress in non-pharmaceutical partnerships and a recent capital raise.

Dyadic International's Q1 2024 report highlights a net loss of $2 million alongside a strategic $6 million capital raise and advancements in its C1 protein production platform for both pharmaceutical and non-pharmaceutical applications.